Intra-Cellular's drug for depression meets main goal in late-stage trial

Intra-Cellular Therapies

18/06/2024 16:31

** Shares of drugmaker Intra-Cellular Therapies  ITCI.O 
rise as much as 11.1% to a near two-month high of $76.50 
    ** Co's drug lumateperone showed a change in severity of
depression vs placebo, meeting the main goal of a late-stage
trial
    ** ITCI expects to submit an application to the U.S. FDA
seeking expanded approval of lumateperone as a treatment of
major depressive disorder in H2 2024
    ** The drug, branded Calypta, is already approved for
schizophrenia and depressive episodes related to types of
bipolar disorders
    ** YTD, stock up 6.6%

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))